Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis
|ClinicalTrials.gov Identifier: NCT00050882|
Recruitment Status : Completed
First Posted : December 31, 2002
Last Update Posted : June 24, 2005
This study is intended to evaluate the potential to relieve the symptoms associated with gastroparesis during 12 weeks of treatment with oral tablets given twice a day of GM-611 5mg, 10mg or placebo to type I or II diabetics who require insulin.
Additionally the study will evaluate the safety and tolerability of GM-611 compared to placebo, the levels of GM-611 in the blood, and the possible effect of GM-611 on diabetic control.
|Condition or disease||Intervention/treatment||Phase|
|Gastroparesis||Drug: GM-611||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A 12-Week Study Conducted at Multiple Centers, Blinded to Both the Patient and Doctor, Evaluating for Safety and Effectiveness Two Dosages of an Investigational Agent (GM-611) Versus a Placebo, That Are Randomly Assigned to Patients With Diabetic Gastroparesis|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00050882
Show 67 Study Locations